Bryan Garnier - ONWARD OPPORTUNITIES LIMITED (ONWD) ONWARD Medical: officially becomes a BCI company

Report

Bryan Garnier

Maria Vara

ONWARD Medical: officially becomes a BCI company

This morning, ONWARD announced that it has entered an exclusive R&D and commercialisation licence agreement with its BCI partner CEA-CLINATEC concerning the WIMAGINE BCI as an integral part of ONWARD's ARC-BCI System. While the company focuses on bringing ARC-EX to market by YE 2024, we see thi

15/10/2024 1 EN

Underlying

ONWARD OPPORTUNITIES LIMITED

See profile

GG00BMZR1514 London Stock Exchange Guernsey

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Maria Vara

Other Reports on these Companies

Bryan Garnier

ONWARD Medical: listing on Euronext Paris tomorrow, non-dilutive offering

On Friday post-market, ONWARD Medical announced that its shares will begin trading on Euronext Paris as of tomorrow 24th September, complementing its existing listings on Euronext Brussels and Amsterdam. As a non-dilutive offering, we view this as a positive move to enhance access for French retail

September 23, 2024 September 23, 2024 1 EN

Bryan Garnier

ONWARD Medical: third successful ARC BCI implantation!

We are pleased to see that clinical developments on the BCI front are running smoothly! This morning, ONWARD announced that it has successfully implanted the ARC-BCI system in another SCI participant aiming to restore lower limb mobility. As was planned according to the EIC funding granted in 2022,

September 19, 2024 September 19, 2024 1 EN

Alfen: 2025 guidance unveiled

This morning, Alfen has provided initial elements from its strategy validation and cost reduction measures assessment. Based on these elements, Alfen has drawn up sluggish 2025 guidance, eyeing limited revenue growth in FY25 compared to FY24 (vs cons. at 15% with revenue estimates standing at EUR48

5h / 6m 5h / 6m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Fastned: impressive gross margin in Q3

Fastned has published its Q3 2024 key metrics and reiterated FY24 guidance this morning. Q3 sales came in at EUR21.9m (+44% YoY), implying 9M revenue of EUR59.7m and an annual run-rate of EUR87.6m (vs cons. at EUR88.0m). Fastned posted a gross margin of 83% (+8ppt vs Q3 2023 at 75%, and cons. expec

5h / 12m 5h / 12m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ONWARD Medical: officially becomes a BCI company

ONWARD Medical: listing on Euronext Paris tomorrow, non-dilutive offering

ONWARD Medical: third successful ARC BCI implantation!

Alfen: 2025 guidance unveiled

Fastned: impressive gross margin in Q3

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe